A comprehensive view of AmerisourceBergen Corp.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AmerisourceBergen serving as generic pharmaceutical firm Civica’s exclusive distribution and supply chain partner for Civica members; partnership being rolled out in phases in first half of 2023 and aims to ensure supply of generic medicines nationwide

AmerisourceBergen to change name to Cencora; as Cencora, the company will continue to invest in and focus on its core pharmaceutical distribution business and grow its pharma and biopharma services platform to support pharmaceutical innovation and access

AmerisourceBergen completes acquisition of PharmaLex, a specialized services provider to the pharmaceutical, biotech medical device industries; deal will build AmerisourceBergen’s European pharmaceutical distribution, biopharma manufacturer services

Fitch: Affirming AmerisourceBergen at A-/F2 on stable outlook, with US$1.5B-US$2B in free cash flow, US$5.7B of outstanding debt; Alliance and PharmaLex acquisitions expected to strengthen company's higher margin services to pharmaceutical manufacturers

Study finds US drug distribution industry expands as COVID-19 disruption fades and biosimilars boom; combined revenue at AmerisourceBergen, Cardinal Health, McKesson projected to reach US$616.0B in 2022: Drug Channels Institute

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count